問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
余文鍾
下載
2025-10-01 - 2030-06-30
Condition/Disease
• The time elapsed before the first occurrence of a CV death or HFE (defined as HHF or emergency HF visit). CV deaths include deaths of unknown cause.
Test Drug
BI 690517 (Vicadrostat) or matching placebo Empagliflozin
Participate Sites13Sites
Recruiting13Sites
2025-10-01 - 2031-04-30
Patients with hereditary transthyretin transporter amyloid polyneuropathy (hATTR-PN)
Nucresiran (ALN-TTRSC04) vutrisiran (ALN-TTRSC02)
Participate Sites3Sites
Recruiting3Sites
2024-09-01 - 2028-12-31
Participate Sites16Sites
Recruiting16Sites
2026-06-01 - 2030-06-30
Participate Sites14Sites
Recruiting14Sites
2025-06-01 - 2027-12-31
Participate Sites8Sites
Recruiting8Sites
2025-07-01 - 2027-12-31
Participate Sites4Sites
Recruiting4Sites
2025-03-01 - 2030-06-30
Participate Sites18Sites
Recruiting18Sites
2024-03-01 - 2027-12-31
Participate Sites20Sites
Not yet recruiting11Sites
2025-07-01 - 2030-12-31
Participate Sites23Sites
Recruiting23Sites
2021-05-01 - 2025-12-31
Recruiting12Sites
全部
